Episode Details
Back to Episodes
256: Explaining the E.U.'s pharma overhaul, Lilly's booming business, & a long-awaited drug approval
Published 3 years, 6 months ago
Description
Andrew Joseph, STAT's Europe correspondent, joins us to explain the EU's sweeping proposal to overhaul how new drugs are regulated on the continent — and why the pharmaceutical industry is fighting it. We also discuss the latest news in the life sciences, including Lilly's surging business, a pair of new drug approvals, and a novel idea in Alzheimer's disease.